[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337475-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337475-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","management-of-renal-cell-carcinoma-promising-biomarkers-and-the-challenges-to-reach-the-clinic","Management of Renal Cell Carcinoma - Promising Biomarkers and the Challenges to Reach the Clinic","","Renal cell carcinoma incidence is rising worldwide while biomarker research lags behind other cancers. Widespread diagnostic CT use increases early detection, yet about one quarter still present with disseminated disease, and another quarter progress to metastasis after curative surgery. Surgery remains foundational for localized RCC, but disseminated disease requires immunotherapy or immunotherapy plus tyrosine kinase inhibition. Despite durable responses, only half benefit and reliable predictors are lacking. The review outlines promising biomarkers, current efforts, and key barriers to achieving robust clinical prognostic and predictive tools.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/management-of-renal-cell-carcinoma-promising-biomarkers-and-the-challenges-to-reach-the-clinic/337475/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/management-of-renal-cell-carcinoma-promising-biomarkers-and-the-challenges-to-reach-the-clinic/337475.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is biomarker development critical in renal cell carcinoma management?","Question",{"text":63,"@type":64},"Current biomarkers are not sufficiently accurate for optimal risk stratification, and there are no routinely used markers to reliably guide clinical decisions. This limits identification of who will benefit from immunotherapy and who is at greatest risk of relapse after surgery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment options are described for localized versus disseminated RCC?",{"text":68,"@type":64},"Localized RCC is addressed with curatively intended approaches such as nephron-sparing surgery, radical nephrectomy, cryoablation, and stereotactic radiotherapy in selected patients. When disease is disseminated, immunotherapy alone or combined with a tyrosine kinase inhibitor is described as the best option.",{"name":70,"@type":61,"acceptedAnswer":71},"How do clinicians assess recurrence risk after definitive surgery for localized RCC?",{"text":72,"@type":64},"Recurrence risk prediction uses prognostic systems or nomograms, including the Leibovich score. Patients are stratified into low, intermediate, and high risk groups based on histologic features and TNM stage, guiding follow-up intensity with CT scan schedules.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337475,1790696495,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic  \nIben Lyskjær1, Laura Iisager1, Christian Tang Axelsen2, Tommy Kjærgaard Nielsen3, Lars Dyrskjøt1, and Niels Fristrup2  \nABSTRACT  \n◥  \nThe incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within this ﬁeld is lagging behind other cancers. Despite increased detection of early disease as a consequence of the widespread use of diagnostic CT scans, 25% of patients have disseminated disease at diagnosis. Similarly, around 25% progress to metastatic disease following curatively intended surgery. Surgery is the cornerstone in the treatment of RCC; however, when the disease is disseminated, immunotherapy or immunotherapy in combination with a tyrosine kinase inhibitor is the patient’s best option. Immunotherapy is a potent treatment, with durable treatment responses and potential to cure the patient, but only half of the patients beneﬁt from the adminis-  \ntered treatment, and there are currently no methods that can identify which patients will respond to immunotherapy. Moreover, there is a need to identify the patients in greatest risk of relapsing after surgery for localized disease and direct adjuvant treatment there. Even though several molecular biomarkers have been published to date, we are still lacking routinely used biomarkers to guide optimal clinical management. The purpose of this review is to highlight some of the most promising biomarkers, discuss the efforts made within this ﬁeld to date, and describe the barriers needed to be overcome to have reliable and robust predictive and prognostic biomarkers in the clinic for renal cancer.  \nIntroduction  \nThe incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within this ﬁeld is lagging behind other cancers. Despite increased detection of early disease, as a consequence of the widespread use of diagnostic CT scans, a quarter of patients have disseminated disease at diagnosis. Similarly, around a quarter progress to metastatic disease following curatively intended surgery.  \nSurgery is the cornerstone in the treatment of localized RCC, however when the disease is disseminated, immunotherapy (IO) or immunotherapy in combination with a tyrosine kinase inhibitor (TKIIO) is the patient’s best option (1–5) .  \nWhen counseling patients on surgical or medical treatments, urologists, and oncologists are utilizing variables such as age, performance status, blood chemistry, and histology in their decision making. These patient characteristics (biomarkers) are guiding treatment decisions to some extent, but not sufﬁciently for optimal risk stratifying.  \nIn this review, we describe the current clinical needs for biomarkers in patient with renal cancer care, and discuss the challenges of biomarker development, including a highlight of the most promising biomarkers today.  \n1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. 2Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 3Department of Urology, Aarhus University Hospital, Aarhus, Denmark.  \nCorresponding Author: Iben Lyskjær, Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, 8200, Denmark. E-mail: [iben.lyskjar@clin.au.dk](iben.lyskjar@clin.au.dk)  \nClin Cancer Res 2024;30:663–72  \ndoi: 10.1158/1078-0432 . CCR-23-1892  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4 . 0 International (CC BY-NC-ND 4 . 0) license.  \n􀀁2023The Authors;Published by the American Association for Cancer Research  \nClinical Challenges in Renal Cancer Management  \nIn this section, we will discuss some of the current challenges inpatient with renal cancer management (Fig. 1) .  \nLocalized disease  \nLocalized RCC can be treated in various curatively intended ways, depending on the size and positioning of the tumor within the kidney. Nephron-sparing surgery is a valid treatment option for ","cbCaiaZV2wKpyrkI","https://ap.wps.com/l/cbCaiaZV2wKpyrkI","pdf",1049320,"English","# Abstract\n# Introduction\n# Clinical Challenges in Renal Cancer Management\n## Localized disease\n## Adjuvant and surveillance decision points","[{\"question\":\"Why is biomarker development critical in renal cell carcinoma management?\",\"answer\":\"Current biomarkers are not sufficiently accurate for optimal risk stratification, and there are no routinely used markers to reliably guide clinical decisions. This limits identification of who will benefit from immunotherapy and who is at greatest risk of relapse after surgery.\"},{\"question\":\"What treatment options are described for localized versus disseminated RCC?\",\"answer\":\"Localized RCC is addressed with curatively intended approaches such as nephron-sparing surgery, radical nephrectomy, cryoablation, and stereotactic radiotherapy in selected patients. When disease is disseminated, immunotherapy alone or combined with a tyrosine kinase inhibitor is described as the best option.\"},{\"question\":\"How do clinicians assess recurrence risk after definitive surgery for localized RCC?\",\"answer\":\"Recurrence risk prediction uses prognostic systems or nomograms, including the Leibovich score. Patients are stratified into low, intermediate, and high risk groups based on histologic features and TNM stage, guiding follow-up intensity with CT scan schedules.\"}]","Management of Renal Cell Carcinoma - Promising Biomarkers and the Challenges to Reach the Clinic | PDF",1790019271,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/915a83805d1f8fe66c930652e9ff0ea9.webp",983,1286,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4aafc5fc9e796e12e624cac2d3e9206.webp",982,1285,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b61c25a965f9790fa0c1bc02f820d2fd.webp",981,1283,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d144221c972a1de0e3760b0611fc23db.webp",980,1282]